Company Profile

Macrogenics Inc
Profile last edited on: 4/5/2022

Antibody-based therapies for autoimmune and infectious diseases and cancer
Year Founded
First SBIR Year
Latest SBIR Award
Program Status


Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9640 Medical Center Drive
Rockville, MD 20850
   (301) 251-5172
Multiple Locations:   
Congressional District:   08
County:   Montgomery

Public Profile

Macrogenics Inc is focused on exploiting the mechanisms by which cytotoxic antibodies mediate cell killing both for the development and improvement of existing therapeutic antibodies for the treatment of cancers and the development of therapeutics to prevent cytotoxic autoantibodies from triggering disease in autoimmunity. The firm is focused on product development derived from in-house and from in-licensed candidates in the areas of oncology, autoimmunity, antibody engineering and infectious disease. This multi-faceted approach in developing both antibodies and vaccines provides a diversified strategy for creating novel immunotherapeutics in areas of unmet medical need.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Scott Koenig -- Chief Exec. Officer, Pres and Director

  Ezio Bonvini -- Senior Vice President, Research

  Stacy E Ferguson --

  Leslie Johnson --

  Syd Johnson --

  Christopher T Rankin --

  Michel Schummer --

  Jeffrey B Stavenhagen --

  Kathryn F Sykes --

  Larry W Tjoelker --

  Maria Concetta Veri --

  Sujata Vijh --

  Priska D Von Haller --

SBIR firms in the news

There are no news available.